Navigation Links
Clinical trial for new tuberculosis vaccine
Date:9/11/2008

This release is available in German.

Since Monday of this week, the new vaccine "VPM1002" has entered the clinical phase I trial in Neuss, Germany, where it is being tested for safety on voluntary subjects. VPM1002 is based on a vaccine that has been in use since 1921, and has been genetically engineered to prevent infection with tuberculosis bacteria much more effectively than its predecessor.

The scientific basis for this was laid down by the team working with Stefan H.E. Kaufmann, Director at the Max Planck Institute for Infection Biology. "The BCG tuberculosis vaccine, which was developed by French researchers, is the most frequently administered live vaccine in the world," says Kaufmann. However, BCG (short for the bacterium Bacillus Calmette-Gurind) is now frequently ineffective. The immunologist continues: "BCG has become a blunt weapon. We wanted to use genetic engineering to sharpen it so that, rather than hiding from the human immune system, it would stimulate it as much as possible."

To do this, the researchers inserted a gene into the vaccine bacteria. Leander Grode, who at the time was a member of Stefan H.E. Kaufmann's staff and is today heads a project at Vakzine Projekt Management GmbH (VPM), describes the process: "The vaccine bacteria are taken up by the scavenger cells of the human immune system and end up in their digestion chambers. The genetically engineered modification allows them to escape from the chambers and arm the immune system against the tuberculosis pathogens."

The scientific studies were initially undertaken at the Max Planck Institute for Infection Biology. In 2004, the vaccine was licensed to the Hanover-based VPN, which expedited the clinical study. Thus far, the new vaccine has proven to be extremely effective and safe in animal models. "We now need to prove that it has the same positive effect on humans, so that it qualifies for a license," explains VPM CEO Bernd Eisele. Kaufmann urges patience: "Even if the new vaccine proves to be well-tolerated, it will still have to undergo more testing to establish its efficacy. That will take at least ten years." Nevertheless - this new approach is looking hopeful.

The establishment of the Max Planck Institute for Infection Biology in 1993 was one of the first in the newly-formed German states (which previously had made up East Germany). The Institute is located on the historical Charit Mitte campus, where, 100 years ago, Robert Koch and Emil Behring made important discoveries about infectious diseases. A key reason for choosing this location was the desire to work together with the universities and clinics on clinically relevant infectious disease projects. "Interdisciplinary research into the molecular and cellular basis of infections enables the systematic development of new therapeutic and preventative measures. Basic research into infectious processes can therefore not only explain fundamental questions in biomedicine, but also make a contribution to solving significant problems in healthcare policy in the future," says Stefan H.E. Kaufmann. VPM was set up by the Federal Ministry for Education and Research and the Helmholtz Center for Infection Research as a private-public partnership. "We ensure that excellent results from basic research benefit humankind and find their way into practical applications," says Bernd Eisele.


'/>"/>

Contact: Prof. Stefan H.E. Kaufmann
kaufmann@mpiib-berlin.mpg.de
49-302-846-0500
Max-Planck-Gesellschaft
Source:Eurekalert  

Related biology news :

1. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
2. New study spotlights National Institutes of Health grant outcomes for clinical research
3. NCI grant launches clinical trials for colon cancer screening
4. Florida researchers receive JDRF Excellence in Clinical Research Award
5. A nutritional supplement could improve the clinical situation of ICU patients
6. NIH expands national consortium dedicated to transforming clinical and translational research
7. Peter J. McGuire, MB BCh, is awarded the 2008-2009 Genzyme/ACMGF Clinical Genetics Fellowship
8. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
9. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
10. NHLBI issues first US von Willebrand Disease clinical practice guidelines
11. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial for new tuberculosis vaccine
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Access System Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 15.1% over the next ... This industry report analyzes the market estimates and forecasts for all ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...
(Date:10/11/2017)... ... 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back for its 4th ... in San Francisco, CA. The Summit brings together current and former FDA office bearers, ... and government officials from around the world to address key issues in device compliance, ...
(Date:10/11/2017)... ... , ... Disappearing forests and increased emissions are the main causes of the ... Especially those living in larger cities are affected by air pollution related diseases. , ... pollution-affected countries globally - decided to take action. , “I knew I had to ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology: